Table 2

Summary of secondary efficacy results

Placebo (N=130)ADA 80/40 (N=130)ADA 160/80 (N=130)
Clinical response44.6%51.5%54.6%
Mucosal healing41.5%37.7%46.9%
Rectal bleeding subscore ≤166.2%70.0%77.7%*
PGA subscore ≤146.9%53.8%60.0%
Stool frequency subscore ≤137.7%36.2%48.5%
  • * p=0.038.

  • p=0.035 versus placebo.

  • ADA, adalimumab; PGA, physician's global assessment.